To ask the Scottish Executive whether it has issued guidelines to NHS boards on the principles and timelines that should govern recommendations by area drugs and therapeutics committees (ADTCs) when reviewing new medicines approved by the Scottish Medicines Consortium and, if so, whether such guidelines deal with the (a) statement in CEL 17 (2010) on the principles determining how new medicines should be measured against other available medicines, (b) relevance of the medicine to approved treatment protocols, (c) basis on which ADTCs reject inclusion in local formularies, (d) resource and (e) service implications.